Dr. Young joined Novavax’ Board of Directors in April 2010 and was appointed Chairman in April 2011. He has over 30 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. Most recently, Dr. Young was MedImmune’s President of Research and Development, where he had responsibility for regulatory affairs and was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics. Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York, NY. He received his doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas and Bachelor of Science degrees in biology and general sciences from Villanova University. 

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.